Indications -- Cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	3/8/2005 7:42:25 PM
	Read Replies (2) of 1840

Is there any ethic, or they think that supportive care is sufficient compensation for placebo group? Miljenko Press Release Source: Bayer Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc. Bayer and Onyx Announce Initiation of Phase III Clinical Trial of BAY 43-9006 In Patients with Advanced Primary Liver Cancer Tuesday March 8, 7:00 am ET WEST HAVEN, Conn., and EMERYVILLE, Calif., March 8 /PRNewswire-FirstCall/ -- Bayer Pharmaceuticals Corporation (NYSE: BAY - News) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) today announced the initiation of a randomized, double-blind, placebo-controlled Phase III clinical trial of BAY 43-9006 administered as a single agent in patients with advanced hepatocellular carcinoma (HCC), or liver cancer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next